Biotech

All Articles

Bicara, Zenas find IPOs to push late-phase resources towards market

.Bicara Therapies and also Zenas Biopharma have actually supplied new inspiration to the IPO market ...

Genentech to finalize cancer cells immunology investigation division

.Genentech will certainly close its cancer cells immunology investigation department, and device hea...

Kezar drops strong lump yet to show its really worth in period 1 trial

.Kezar Life Sciences is dropping its unpromising phase 1 sound growth medicine as the biotech goes a...

Acelyrin loses izokibep, dismisses 3rd of personnel

.Even with izokibep preserving its own newfound winning streak in the medical clinic, Acelyrin is no...

Rivus' stage 2 obesity-related cardiac arrest test attacks endpoint

.Rivus Pharmaceuticals has actually plumped up the leads of its own fat-busting, muscle-sparing medi...

Ovid stops preclinical work, IV plan after soticlestat stop working

.Ovid Therapeutics presently showed last month that it was trimming its headcount as the firm naviga...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston ma Port

.Eli Lilly has opened a $700 million R&ampD center in the Boston Seaport, enhancing its RNA and DNA ...

Boundless Bio helps make 'small' discharges five months after $100M IPO

.Just five months after getting a $100 thousand IPO, Limitless Biography is presently laying off som...

Halda's $126M will evolve 'hold as well as eliminate' growth medicines

.The preliminary stages of oncology R&ampD may not be except fascinating brand new modalities, and a...

Lykos 'disappointments' not divulging study violations with publisher

.Psychopharmacology has taken three posts regarding midstage scientific test information examining L...